Alzamend Cash And Short Term Investments vs Other Current Liab Analysis

ALZN Stock

USD 0.59 0.03 4.84%

Alzamend Neuro financial indicator trend analysis is way more than just evaluating Alzamend Neuro prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alzamend Neuro is a good investment. Please check the relationship between Alzamend Neuro Cash And Short Term Investments and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Cash And Short Term Investments vs Other Current Liab

Cash And Short Term Investments vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alzamend Neuro Cash And Short Term Investments account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Alzamend Neuro's Cash And Short Term Investments and Other Current Liab is 0.39. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Alzamend Neuro, assuming nothing else is changed. The correlation between historical values of Alzamend Neuro's Cash And Short Term Investments and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Alzamend Neuro are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Cash And Short Term Investments i.e., Alzamend Neuro's Cash And Short Term Investments and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Alzamend Neuro balance sheet. This account contains Alzamend Neuro investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Alzamend Neuro fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Other Current Liab

Most indicators from Alzamend Neuro's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alzamend Neuro current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.As of the 24th of May 2024, Issuance Of Capital Stock is likely to grow to about 6.1 M, while Selling General Administrative is likely to drop about 4.9 M.

Alzamend Neuro fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Deferred Long Term Liab	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital
Total Current Liabilities		0.31	-0.9	0.98	0.14	-0.26	-0.79	0.47	0.75	0.48	0.8	0.97	0.35	0.34	-0.46	0.49	0.49	0.83	0.79	-0.96	-0.63	0.83	0.96	0.35	0.83	0.35
Net Tangible Assets	0.31		-0.62	0.41	-0.08	0.0	-0.19	0.98	0.71	0.96	0.66	0.22	0.98	0.61	-0.96	0.96	0.96	0.68	0.28	-0.21	-0.82	0.65	0.23	0.98	0.68	0.98
Retained Earnings	-0.9	-0.62		-0.94	0.02	0.18	0.59	-0.75	-0.93	-0.73	-0.93	-0.86	-0.62	-0.65	0.72	-0.74	-0.74	-0.93	-0.69	0.88	0.8	-0.96	-0.83	-0.62	-0.93	-0.61
Accounts Payable	0.98	0.41	-0.94		0.0	-0.11	-0.76	0.56	0.83	0.54	0.82	0.95	0.42	0.42	-0.52	0.55	0.55	0.85	0.79	-0.94	-0.65	0.86	0.94	0.42	0.86	0.41
Other Assets	0.14	-0.08	0.02	0.0		-0.79	-0.12	-0.06	-0.26	0.12	-0.03	0.16	0.08	-0.37	-0.12	0.12	0.12	0.14	0.3	-0.05	-0.23	0.03	0.22	0.07	0.13	0.08
Net Receivables	-0.26	0.0	0.18	-0.11	-0.79		0.15	-0.05	0.04	-0.21	-0.29	-0.2	-0.19	-0.07	0.22	-0.22	-0.22	-0.24	-0.13	0.19	0.31	-0.24	-0.2	-0.19	-0.24	-0.19
Deferred Long Term Liab	-0.79	-0.19	0.59	-0.76	-0.12	0.15		-0.25	-0.41	-0.29	-0.6	-0.79	-0.23	0.02	0.27	-0.29	-0.29	-0.5	-0.56	0.73	0.41	-0.49	-0.82	-0.23	-0.51	-0.23
Total Current Assets	0.47	0.98	-0.75	0.56	-0.06	-0.05	-0.25		0.83	0.98	0.75	0.37	0.96	0.66	-0.97	0.98	0.98	0.81	0.43	-0.37	-0.88	0.78	0.37	0.96	0.81	0.96
Common Stock	0.75	0.71	-0.93	0.83	-0.26	0.04	-0.41	0.83		0.76	0.85	0.68	0.66	0.73	-0.74	0.77	0.77	0.92	0.64	-0.72	-0.76	0.94	0.65	0.67	0.92	0.66
Total Assets	0.48	0.96	-0.73	0.54	0.12	-0.21	-0.29	0.98	0.76		0.75	0.38	0.98	0.6	-1.0	1.0	1.0	0.8	0.44	-0.36	-0.9	0.76	0.39	0.98	0.8	0.98
Short Long Term Debt Total	0.8	0.66	-0.93	0.82	-0.03	-0.29	-0.6	0.75	0.85	0.75		0.75	0.67	0.64	-0.74	0.76	0.76	0.86	0.5	-0.78	-0.85	0.91	0.72	0.68	0.86	0.67
Other Current Liab	0.97	0.22	-0.86	0.95	0.16	-0.2	-0.79	0.37	0.68	0.38	0.75		0.24	0.24	-0.36	0.39	0.39	0.79	0.81	-0.98	-0.58	0.79	0.99	0.24	0.79	0.23
Total Stockholder Equity	0.35	0.98	-0.62	0.42	0.08	-0.19	-0.23	0.96	0.66	0.98	0.67	0.24		0.58	-0.99	0.98	0.98	0.68	0.29	-0.21	-0.84	0.64	0.25	1.0	0.68	1.0
Current Deferred Revenue	0.34	0.61	-0.65	0.42	-0.37	-0.07	0.02	0.66	0.73	0.6	0.64	0.24	0.58		-0.6	0.6	0.6	0.55	0.09	-0.38	-0.44	0.66	0.16	0.59	0.55	0.58
Net Debt	-0.46	-0.96	0.72	-0.52	-0.12	0.22	0.27	-0.97	-0.74	-1.0	-0.74	-0.36	-0.99	-0.6		-1.0	-1.0	-0.77	-0.4	0.34	0.9	-0.73	-0.37	-0.98	-0.77	-0.99
Cash	0.49	0.96	-0.74	0.55	0.12	-0.22	-0.29	0.98	0.77	1.0	0.76	0.39	0.98	0.6	-1.0		1.0	0.81	0.44	-0.37	-0.92	0.77	0.4	0.98	0.81	0.98
Cash And Short Term Investments	0.49	0.96	-0.74	0.55	0.12	-0.22	-0.29	0.98	0.77	1.0	0.76	0.39	0.98	0.6	-1.0	1.0		0.81	0.44	-0.37	-0.92	0.77	0.4	0.98	0.81	0.98
Common Stock Total Equity	0.83	0.68	-0.93	0.85	0.14	-0.24	-0.5	0.81	0.92	0.8	0.86	0.79	0.68	0.55	-0.77	0.81	0.81		0.82	-0.78	-0.86	0.98	0.78	0.68	1.0	0.67
Common Stock Shares Outstanding	0.79	0.28	-0.69	0.79	0.3	-0.13	-0.56	0.43	0.64	0.44	0.5	0.81	0.29	0.09	-0.4	0.44	0.44	0.82		-0.74	-0.55	0.73	0.84	0.27	0.82	0.28
Non Current Liabilities Total	-0.96	-0.21	0.88	-0.94	-0.05	0.19	0.73	-0.37	-0.72	-0.36	-0.78	-0.98	-0.21	-0.38	0.34	-0.37	-0.37	-0.78	-0.74		0.54	-0.81	-0.95	-0.21	-0.78	-0.2
Other Current Assets	-0.63	-0.82	0.8	-0.65	-0.23	0.31	0.41	-0.88	-0.76	-0.9	-0.85	-0.58	-0.84	-0.44	0.9	-0.92	-0.92	-0.86	-0.55	0.54		-0.83	-0.59	-0.84	-0.86	-0.84
Other Stockholder Equity	0.83	0.65	-0.96	0.86	0.03	-0.24	-0.49	0.78	0.94	0.76	0.91	0.79	0.64	0.66	-0.73	0.77	0.77	0.98	0.73	-0.81	-0.83		0.76	0.64	0.98	0.64
Total Liab	0.96	0.23	-0.83	0.94	0.22	-0.2	-0.82	0.37	0.65	0.39	0.72	0.99	0.25	0.16	-0.37	0.4	0.4	0.78	0.84	-0.95	-0.59	0.76		0.24	0.78	0.24
Net Invested Capital	0.35	0.98	-0.62	0.42	0.07	-0.19	-0.23	0.96	0.67	0.98	0.68	0.24	1.0	0.59	-0.98	0.98	0.98	0.68	0.27	-0.21	-0.84	0.64	0.24		0.68	1.0
Capital Stock	0.83	0.68	-0.93	0.86	0.13	-0.24	-0.51	0.81	0.92	0.8	0.86	0.79	0.68	0.55	-0.77	0.81	0.81	1.0	0.82	-0.78	-0.86	0.98	0.78	0.68		0.67
Net Working Capital	0.35	0.98	-0.61	0.41	0.08	-0.19	-0.23	0.96	0.66	0.98	0.67	0.23	1.0	0.58	-0.99	0.98	0.98	0.67	0.28	-0.2	-0.84	0.64	0.24	1.0	0.67

Click cells to compare fundamentals

Alzamend Neuro Account Relationship Matchups

Alzamend Neuro fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	992.3K	899.6K	1.2M	2.9M	3.3M	3.5M
Net Tangible Assets	821.6K	2.0M	13.4M	3.0M	3.5M	3.3M
Retained Earnings	(11.8M)	(16.8M)	(29.2M)	(44.1M)	(39.7M)	(37.7M)
Accounts Payable	929.6K	503.6K	1.2M	2.9M	3.3M	3.5M
Net Receivables	424.4K	285.4K	194.3K	16.2K	14.6K	13.9K
Total Current Assets	1.8M	2.9M	14.4M	5.8M	6.7M	4.5M
Common Stock	6.5K	6.7K	9.5K	9.7K	11.1K	7.4K
Total Assets	1.8M	2.9M	14.5M	5.9M	6.8M	5.9M
Other Current Liab	62.7K	60.7K	2.1K	2.9M	3.3M	3.5M
Total Stockholder Equity	821.7K	2.0M	13.4M	3.0M	3.5M	4.3M
Net Debt	(90.2K)	(1.6M)	(14.1M)	(5.1M)	(4.6M)	(4.9M)
Cash	90.3K	1.9M	14.1M	5.1M	5.9M	4.7M
Cash And Short Term Investments	90.3K	1.9M	14.1M	5.1M	5.9M	4.7M
Common Stock Total Equity	6.5K	6.7K	9.5K	9.7K	11.1K	8.5K
Liabilities And Stockholders Equity	1.8M	2.9M	14.5M	5.9M	6.8M	5.9M
Other Current Assets	1.5M	983.3K	349.7K	694.9K	625.4K	756.9K
Other Stockholder Equity	27.6M	33.7M	42.5M	47.1M	54.2M	38.2M
Total Liab	992.3K	899.6K	1.2M	2.9M	3.3M	3.5M
Net Invested Capital	821.6K	2.3M	13.4M	3.0M	3.5M	4.4M
Capital Stock	6.6K	6.8K	9.5K	9.7K	11.1K	8.6K
Net Working Capital	821.7K	2.0M	13.2M	3.0M	3.4M	4.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:

How To Invest In Alzamend

Details

Is Alzamend Stock a good investment?

Details

What is Alzamend Neuro's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Note that the Alzamend Neuro information on this page should be used as a complementary analysis to other Alzamend Neuro's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Alzamend Stock analysis

When running Alzamend Neuro's price analysis, check to measure Alzamend Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alzamend Neuro is operating at the current time. Most of Alzamend Neuro's value examination focuses on studying past and present price action to predict the probability of Alzamend Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alzamend Neuro's price. Additionally, you may evaluate how the addition of Alzamend Neuro to your portfolios can decrease your overall portfolio volatility.

	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Commodity Directory Find actively traded commodities issued by global exchanges
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Alzamend Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.82)

Return On Assets

(1.67)

Return On Equity

(11.96)

The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alzamend Cash And Short Term Investments vs Other Current Liab Analysis

Cash And Short Term Investments vs Other Current Liab

Cash And Short Term Investments vs Other Current Liab Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Other Current Liab

Alzamend Neuro fundamental ratios Correlations

Alzamend Neuro Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alzamend Neuro fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Alzamend Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Capital Stock	+ 1.0	Common Stock Total Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Working Capital	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Invested Capital	- 0.98	Net Debt